Red Light Therapy for Eyes: 3 Uses Tested, None With a Home Panel

Quick Answer: Red light has been tested on the eye for three different jobs, and none of the trials used a home red light panel. Dry age-related macular degeneration (AMD): in November 2024 the FDA authorized one device, the Valeda Light Delivery System, as a prescription treatment given in an eye clinic, 9 sessions every 4 months. In its main trial, treated eyes ended up 3.8 letters better than sham at month 21 on the eye chart, and FDA’s summary records more conversions to wet AMD in the treated group. Childhood myopia: Chinese trials of a desktop red laser device slowed eye growth, but the effect partly rebounded when children stopped, and we found no FDA clearance for these devices. Ageing eyesight: the widely shared “3 minutes a day” study measured colour contrast in 20 people, not sharpness of vision, and described no sham group. There is no advertisement on this page; see why below.

“Red light therapy for eyes” and “red light therapy for eyesight” are searched thousands of times a month. The answers usually blur three separate things: a clinic device for a retinal disease, a laser instrument for children’s short-sightedness, and a small laboratory study in healthy adults. This page keeps them apart. For the eye risks, including laboratory measurements of the myopia devices, see our red light therapy dangers page; for red light therapy’s other uses, see red light therapy benefits.

The 3 eye uses at a glance

Dry AMD: the one FDA-authorized red light eye device

Dry AMD is the common form of macular degeneration, in which the centre of the retina slowly thins. It is the condition the Valeda system is authorized for, in people whose vision is between 20/32 and 20/70 and whose retina shows medium or large drusen (yellow deposits) or non-central geographic atrophy.

What the treatment actually is

According to FDA’s decision summary, each session runs through set phases with the eyes open and closed: pulsed amber (590 nm) and near-infrared (850 nm) light for 35 seconds with the eyes open, and continuous red (660 nm) light for 90 seconds with the eyes closed. A treatment series is 3 sessions a week for 3 to 5 weeks, 9 in total. In the pivotal trial, patients received a new series every 4 months, 6 series over 2 years. FDA restricts the device to prescription use, and the labelling warns that “it is possible that treatment benefit may not persist significantly after treatment is stopped.”

What the main trial found

LIGHTSITE III randomised 100 people (148 eyes) with dry AMD to the device or a sham version, in which the infrared light was switched off and the visible light was much dimmer. Vision was scored as letters read on a standard eye chart.

• Month 13: FDA’s summary records the treated eyes as 2.6 letters better than sham, “non-significant” (p = 0.0548) in the analysis FDA used. The company’s published 13-month paper, using a different analysis, reported 2.4 letters and P = 0.02.
• Month 21, the endpoint the trial met: 3.8 letters better than sham (p = 0.0036). The 24-month paper reports a +6.2 letter gain in treated eyes.
• Losing vision: 7% of treated eyes had lost more than 5 letters by month 24, against 18% of sham eyes.
• Geographic atrophy, the advanced stage of dry AMD: new cases at 24 months were 6.8% with treatment and 24.0% with sham.

Five letters is one line on an eye chart. The differences above are smaller than a line on average, which is why reviewers disagree about how much they matter.

The wet AMD signal

FDA’s summary states that “the treatment arm in the LIGHTSITE III study observed a higher rate of progression to neovascular AMD (nAMD) than the sham arm.” Wet (neovascular) AMD is the faster, more serious form. The clearest numbers are in eyes whose other eye already had wet AMD: 5 of 12 treated eyes converted, against 1 of 4 sham eyes. FDA wrote that uncertainty remains whether this was caused by “an imbalance in baseline risk factors between the two study arms, random variability in rates of progression, an effect of the treatment, or a combination of these factors,” and the labelling tells eye doctors to monitor these patients closely. For patients with early AMD, the summary reports a difference of +0.29 letters at month 24.

What independent reviews concluded

• Cochrane, 2021 (before LIGHTSITE III was published): two small trials, 106 eyes. There was “no evidence of any meaningful clinical difference” in visual acuity at 12 months, and the reviewers wrote there “remains uncertainty whether PBM treatment is beneficial in slowing progression.”
• 2024 meta-analysis, 3 trials, 247 eyes: 1.76 letters better than sham, but the statistically significant results “did not translate into clinically significant benefits,” and all studies were judged at high risk of bias.
• 2025 meta-analysis, 6 studies, 477 eyes: no significant improvement in visual acuity, and the authors concluded there are “no significant clinical benefits” to date.

Several authors of the LIGHTSITE III papers are employees of, or consultants to, the manufacturer, LumiThera, as the papers declare.

Myopia in children: a laser, not a panel

The second use is very different. Here children look into a small desktop instrument that shines a 650 nm red light into the eye for 3 minutes, twice a day, 5 days a week, at home. The aim is to slow the lengthening of the eyeball that makes short-sightedness worse each year.

What the trials found

• The first large trial (2022): 264 children aged 8 to 13 in China. Over 12 months the eye grew 0.13 mm with red light and glasses, against 0.38 mm with glasses alone. The control group did not receive a sham device, and the trial was single-blind.
• Prevention (2023): 278 children with “premyopia” in Shanghai schools. After a year, 40.8% of the red light group had become myopic, against 61.3% of the control group.
• Stopping (2-year follow-up): children who stopped red light after the first year saw their eyes grow 0.42 mm in the second year, more than the 0.28 mm in children who had worn glasses throughout. The authors called it “a modest rebound effect.”
• All the trials (2026 meta-analysis): 28 randomised trials with 3,573 children found myopia control that grew with treatment duration, with moderate-certainty evidence for the refraction result and lower certainty for eye length. The authors wrote that “longer-term trials incorporating comprehensive retinal safety assessment are required.”

Two of the key trials declare that their senior author holds patents on the treatment and is a director and shareholder of Eyerising, a company that makes one of the devices.

The safety question

These devices aim light directly into the eye. In a 2026 laboratory test of four instruments sold for myopia, two laser devices reached the eye-safety exposure limit for a 7 mm pupil in 2.8 and 1.4 seconds; the treatment session is 3 minutes. An LED-based device took over six hours. A 2023 case report described retinal damage in a 12-year-old after repeated use. Our dangers page covers these findings in full.

Is it available in the US?

In FDA’s 510(k) clearance and premarket approval databases (searched 22 October 2026) we found no red light device for myopia. The myopia-control product with FDA premarket approval is a contact lens, MiSight 1 Day. An eye doctor is the person to ask about the options.

Ageing eyesight: the “3 minutes a day” study

The third use is the one that went viral. Researchers at University College London’s Institute of Ophthalmology reported in 2020 that 670 nm light improved colour contrast sensitivity for the blue axis in people around 40 and older, while having “no impact in younger individuals.” In a 2021 follow-up, a single 3-minute exposure in the morning, at 8 mW/cm², improved blue-axis colour contrast thresholds for up to a week in 20 healthy people aged 37 to 70; across the group, thresholds fell by 17%.

What those studies did not show:

• Sharper vision. They measured how faint a coloured letter can be before you stop seeing it, not visual acuity (how many lines you can read on an eye chart).
• A comparison group. The 2021 paper describes no sham or placebo exposure; people were compared with their own baseline.
• Disease. Participants were healthy. The results say nothing about AMD, glaucoma or cataract.

It is interesting laboratory research. It is not evidence that a red light panel improves eyesight.

Eyes open or closed with a home panel?

None of the three uses above tested a home panel, mask or wand pointed at the face. The clinic device alternates open-eye and closed-eye phases at set doses, and the myopia devices are aimed into the eye on purpose, which is exactly where the safety concerns lie. With a panel sold for skin or general use, there is no eye benefit on record to set against those risks, so keep your eyes closed or covered and do not look into the light.

Why there is no advertisement on this page

We carry advertising for a red light device maker on other red light therapy pages. We are not placing it here. The only FDA-authorized red light eye treatment is a prescription device used in eye clinics, and no consumer panel, mask or lamp we know of has been tested to improve eyesight. Advertising a device next to a page about eyes would suggest otherwise.

Who should see an eye doctor first

• Anyone with blurred or distorted central vision, straight lines that look wavy, or a new dark patch in the centre of vision. These can be signs of AMD, and the wet form needs urgent treatment.
• Anyone already diagnosed with dry AMD who is considering light therapy, especially if the other eye has wet AMD (see the FDA signal above).
• Parents considering red light treatment for a child’s myopia, so that the child’s retina can be examined before and during treatment.
• Anyone taking a medicine that makes the eyes or skin sensitive to light.

Frequently Asked Questions

Does red light therapy improve eyesight?

Not in the sense most people mean. In the one FDA-authorized use, dry AMD, treated eyes ended up 3.8 letters better than sham on an eye chart at 21 months in the main trial, less than one line. The “3 minutes a day” studies in healthy older adults measured colour contrast, not sharpness, in 20 people without a sham group.

Is red light therapy FDA approved for eyes?

One device is FDA-authorized: the Valeda Light Delivery System, granted De Novo authorization on 4 November 2024 for certain patients with dry age-related macular degeneration. It is prescription-only and used in eye clinics. We found no FDA clearance for red light devices sold to treat myopia.

Does red light therapy work for myopia?

In trials, mostly in China, a desktop red laser device used for 3 minutes twice a day slowed eye growth in children: 0.13 mm versus 0.38 mm in one year in the first large trial. The effect partly rebounded when children stopped, and laboratory tests found some of these lasers reach eye-safety limits in seconds.

Should you close your eyes during red light therapy?

With a home panel or mask, yes, or wear the eye protection supplied. No trial has shown an eye benefit from home panels, and the documented eye harms come from light aimed into the eye. The clinic device for dry AMD uses the eyes-open phases at controlled doses under prescription.

Can red light therapy help macular degeneration?

For dry AMD, one prescription device has FDA authorization based on a 100-person trial in which treated eyes lost vision less often (7% versus 18% lost more than 5 letters by 24 months). Independent reviews were less convinced, and FDA noted more conversions to wet AMD in the treated group. It is not a treatment for wet AMD.

Is red light therapy safe for your eyes?

It depends on the device. Laboratory tests found two laser devices sold for children’s myopia reached eye-safety limits in 1.4 and 2.8 seconds, and a case of retinal damage has been published. An LED-based device took over six hours. With any panel, avoid looking into the light.

The Bottom Line

Red light therapy for the eyes is three different things. For dry AMD there is one prescription clinic device, authorized by FDA in 2024 on the basis of a modest letter gain and fewer eyes losing vision, with an unresolved wet AMD signal. For children’s myopia there are many Chinese trials of a laser device that slows eye growth while it is used, a partial rebound when it stops, real eye-safety questions, and no FDA clearance. For ageing eyesight there is a small study of colour contrast without a sham group. None of it is evidence for using a home red light panel on your eyes, and with a panel the safest advice is to keep your eyes closed.

Sources

1. US Food and Drug Administration. De Novo classification request DEN230083, Valeda Light Delivery System (LumiThera, Inc.), decision summary. accessdata.fda.gov. Granted 4 November 2024; 21 CFR 886.5520, product code SDE, Class II, prescription use; protocol 590/850 nm open eye 35 s, 660 nm closed eye 90 s, 9 treatments over 3-5 weeks; Month 13 +2.6 letters (p=0.0548, non-significant), Month 21 +3.8 letters (p=0.0036); >5-letter loss at Month 24 7% vs 18%; fellow-eye nAMD subgroup 5 of 12 vs 1 of 4 converted; early AMD +0.29 letters at Month 24. Checked 22 October 2026.
2. Boyer D, et al. LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the LumiThera Valeda Light Delivery System. Retina, 2024;44(3):487-497. PMID 37972955. 100 subjects, 148 eyes; between-group difference 2.4 letters, P = 0.02; authors include LumiThera employees/contractors. Checked 22 October 2026.
3. Jaffe GJ, et al. Long-term efficacy and safety of photobiomodulation in dry age-related macular degeneration (LIGHTSITE III: 24-month analysis). Retina, 2026;46(5):783-795. PMID 41791029. Primary endpoint met at month 21 (P = 0.0036), +6.2 letter gain after PBM; geographic atrophy 24.0% sham vs 6.8% PBM at month 24 (P = 0.007). Checked 22 October 2026.
4. Henein C, Steel DH. Photobiomodulation for non-exudative age-related macular degeneration. Cochrane Database Syst Rev, 2021;5:CD013029. PMID 34097768. 2 RCTs (60 and 46 eyes); BCVA MD 0.02 logMAR, “no evidence of any meaningful clinical difference”; “there remains uncertainty whether PBM treatment is beneficial”. Checked 22 October 2026.
5. Rassi TNO, Barbosa LM, et al. Photobiomodulation efficacy in age-related macular degeneration: a systematic review and meta-analysis of randomized clinical trials. Int J Retina Vitreous, 2024;10(1):54. PMID 39148091. 3 RCTs, 247 eyes; BCVA MD 1.76 letters; “did not translate into clinically significant benefits”; all studies high risk of bias. Checked 22 October 2026.
6. Chen KY, Lee HK, Chan HC, Chan CM. Is multiwavelength photobiomodulation effective and safe for age-related macular degeneration? A systematic review and meta-analysis. Ophthalmol Ther, 2025;14(5):969-987. PMID 40089957. 6 studies, 360 patients, 477 eyes; BCVA SMD -0.30 (p = 0.30); “no significant clinical benefits of PBM therapy”. Checked 22 October 2026.
7. Jiang Y, et al. Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial. Ophthalmology, 2022;129(5):509-519. PMID 34863776. 264 children aged 8-13; 650 nm, 3 minutes twice daily, 5 days a week; single-blind; axial elongation 0.13 mm vs 0.38 mm over 12 months. Checked 22 October 2026.
8. He X, et al. Effect of repeated low-level red light on myopia prevention among children in China with premyopia: a randomized clinical trial. JAMA Netw Open, 2023;6(4):e239612. PMID 37099298. 278 children; 12-month myopia incidence 40.8% vs 61.3%; senior author declares patent and Eyerising directorship. Checked 22 October 2026.
9. Xiong R, et al. Sustained and rebound effect of repeated low-level red-light therapy on myopia control: a 2-year post-trial follow-up study. Clin Exp Ophthalmol, 2022;50(9):1013-1024. PMID 36054314. Second-year axial length change 0.42 mm after stopping vs 0.28 mm with glasses only; “A modest rebound effect was noted after treatment cessation.” Checked 22 October 2026.
10. Lin LY, et al. Duration-dependent efficacy and clinical safety of repeated low-level red-light therapy for paediatric myopia: a systematic review and meta-analysis. Clin Exp Ophthalmol, 2026;54(5):630-652. PMID 41846466. 28 RCTs, 3,573 participants; moderate-certainty evidence for SER; “Longer-term trials incorporating comprehensive retinal safety assessment are required.” Checked 22 October 2026.
11. Ostrin LA, Schill AW. Safety evaluation of 4 red light therapy devices for myopia. JAMA Ophthalmol, 2026. PMID 41642586. Two laser devices reached ANSI group 1 limits in 2.8 and 1.4 seconds for a 7-mm pupil; LED-based device 22,761 seconds. Checked 22 October 2026.
12. Liu H, et al. Retinal damage after repeated low-level red-light laser exposure. JAMA Ophthalmol, 2023. PMID 37227712. Case report, 12-year-old patient with myopia. Checked 22 October 2026.
13. US Food and Drug Administration. openFDA device 510(k) and PMA endpoints, searches for “myopia” and applicant “Eyerising”; PMA P180035, MiSight 1 Day. open.fda.gov. No red light myopia device found. Checked 22 October 2026.
14. Shinhmar H, et al. Optically improved mitochondrial function redeems aged human visual decline. J Gerontol A Biol Sci Med Sci, 2020;75(9):e49-e52. PMID 32596723. 670 nm light, ages 28-72; “had no impact in younger individuals”; tritan colour contrast improved in those around 40 and older. Checked 22 October 2026.
15. Shinhmar H, Hogg C, Neveu M, Jeffery G. Weeklong improved colour contrasts sensitivity after single 670 nm exposures associated with enhanced mitochondrial function. Sci Rep, 2021;11:22872. PMID 34819619. 20 healthy subjects aged 37-70; single 3-minute exposure at 8 mW/cm2; 17% reduction in tritan thresholds; outcome colour contrast thresholds, compared with each person’s baseline. Checked 22 October 2026.